The Minister of Health, Olivier Véran, however, stated on Twitter that, in accordance with presidential announcements, the enlargement of the recall will be done at first at the age of 50.
Emmanuel Macron had announced it: the high health authority (HAS) lowered age from which a recall dose against COVID-19 – for most people, this is a third Injection of vaccine – is recommended. Except that the independent authority went further than the presidential announcements and paved the way for a vaccinal reminder from 40 years, six months after receiving their second injection, In a review published on Friday, November 19th . A little later in the evening, The Minister of Health, Olivier Véran, gave back a setting : “The reminder (…) will be well open to people aged 50 and older in early December as announced by the President of the Republic. The enlargement of the reminder at least 50 years will be studied soon. “
By defining a new threshold at 40, the HAS is placed on the same line as the recommendations made Monday in the United Kingdom but is careful not to cross the Cape Town on the Atlantic, where the US Medicines Agency (FDA ) gave its green light on Friday night to a third dose for all adults. For less than 40 years, the has prefer to suspend its judgment pending new data because “the scarcity of severe cases of the disease or death in the youngest primo-vaccinated does not formally conclude on the reduction. of individual risk in this population “, Can we read in the notice
For more than 40 years, however, data from three recently published studies have convinced the experts of net profit brought by a recall dose. First of all, Israeli real lives exposed in A study published on November 2nd in The Journal of Infectious Diseases demonstrate that the recall dose gives excellent levels of protection, including in patients with less than 60 years old.
Next, a large Israeli observational study and Posted in The Lancet on October 29 brings, according to the experts of the HAS,” solid arguments in favor of a recall dose in the more than 40 years “, citing” decreasing the risk of infection, severe form, hospitalization and death for this population “. Finally, A study conducted by experts from experts The US Centers for Disease Control (CDC) Health Agency confirms the good tolerance of a recall dose with Messenger RNA vaccines at the youngest.
Paradigm Change
In a context of epidemic recovery in France but also in all of Europe, these new elements therefore grow the has to propose a booster dose for a younger audience. “We are changing paradigm. Until then, vaccination was intended to be used to protect the population of the severe forms of CVIV-19, but would not be considered to be considered Decrease the circulation of the virus? “, Ask Jean-Daniel Lelièvre, Chief of the Clinical Immunology Department and Infectious Diseases at Henri-Mondor Hospital of Créteil, but also expert at HAS.
You have 36.16% of this article to be read. The rest is reserved for subscribers.